source
- UCB to buy Candid Therapeutics for up to $2.2 billion, targeting bispecific antibodies for autoimmune diseaseUCB announced a deal to acquire Candid Therapeutics, a startup focused on bispecific antibody drugs, for an upfront payment of $2 billion with up to $200 million in future milestones. The transacti…
- 5th Circuit reinstates in-person dispensing for mifepristone, prompting Supreme Court stay and industry concernsThe 5th Circuit Court of Appeals reversed a prior ruling and required mifepristone to be dispensed only in person. Danco, the drug's maker, asked the Supreme Court for relief and received a one-wee…